Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Ib Study of TBI-2001 for Patients With Relapsed or Refractory CD19+ B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

NCT05963217 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT05963217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05963217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Ib Study of TBI-2001 for Patients With Relapsed or Refractory CD19+ B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Lead sponsor
University Health Network, Toronto
Phase
Phase 1
Overall status
Recruiting
Start date
July 26, 2023
Completion date
June 30, 2028
Enrollment
19 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory cd19+ b-cell lymphoma, relapsed or refractory chronic lymphocytic leukemia, relapsed or refractory small lymphocytic lymphoma